Skip to main content

Table 1 Patient Characteristics (n = 24)

From: Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers

Characteristics No. of Patients (%)
Age, years
 Median 62
 Range 30–72
Sex
 Male 4 (17)
 Female 20 (83)
Race
 White 22 (90)
 Black 0
 Other 2 (10)
ECOG performance status
 ECOG 0 16 (67)
 ECOG 1 7 (29)
 ECOG 2 1 (4)
Tumor type
 Ovarian/fallopian/peritoneal 10 (42)
 Endometrial 5 (21)
 Cervical 3 (13)
 Esophageal 2 (8)
 Urethral 1 (4)
 Vaginal 1 (4)
 Mesothelial 1 (4)
 Salivary 1 (4)
Prior chemotherapiesa
 0 7 (29)
 1 1 (4)
 2 7 (29)
 3 9 (38)
  1. ECOG Eastern Cooperative Oncology Group
  2. aTherapies that included chemotherapy for radiation sensitization only (n = 4), were discontinued due to toxicity without progression (n = 2), were radiation alone (n = 4), or were hormonal only (n = 2) were not included for eligibility